North China Pharmaceutical Company.Ltd (SHA:600812)
4.830
-0.130 (-2.62%)
May 20, 2026, 11:29 AM CST
SHA:600812 Income Statement
Financials in millions CNY. Fiscal year is January - December.
Millions CNY. Fiscal year is Jan - Dec.
Fiscal Year | TTM | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 |
|---|---|---|---|---|---|---|
Period Ending | Mar '26 Mar 31, 2026 | Dec '25 Dec 31, 2025 | Dec '24 Dec 31, 2024 | Dec '23 Dec 31, 2023 | Dec '22 Dec 31, 2022 | Dec '21 Dec 31, 2021 |
Operating Revenue | 8,717 | 9,138 | 9,798 | 10,070 | 10,449 | 10,304 |
Other Revenue | 103.99 | 103.99 | 71.76 | 50.32 | 51.19 | 80.2 |
| 8,821 | 9,242 | 9,870 | 10,120 | 10,500 | 10,385 | |
Revenue Growth (YoY) | -10.78% | -6.36% | -2.48% | -3.62% | 1.11% | -9.64% |
Cost of Revenue | 6,077 | 6,363 | 6,732 | 6,907 | 7,063 | 6,691 |
Gross Profit | 2,744 | 2,878 | 3,138 | 3,213 | 3,437 | 3,694 |
Selling, General & Admin | 1,678 | 1,780 | 2,010 | 2,268 | 2,424 | 2,796 |
Research & Development | 354.42 | 339.77 | 336.15 | 294.2 | 215.17 | 151.93 |
Other Operating Expenses | 93.7 | 87.41 | 90.82 | 104.23 | 117.57 | 123.33 |
Operating Expenses | 2,166 | 2,251 | 2,479 | 2,677 | 2,802 | 3,094 |
Operating Income | 577.45 | 627.16 | 658.87 | 536.44 | 634.8 | 600.11 |
Interest Expense | -339.14 | -361.55 | -458.7 | -501.9 | -599.39 | -642.69 |
Interest & Investment Income | 91.55 | 86.44 | 71.42 | 74.52 | 84.17 | 126.62 |
Currency Exchange Gain (Loss) | -4.96 | -4.96 | 17.57 | 11.49 | 23.31 | -8.32 |
Other Non Operating Income (Expenses) | -17.83 | -5.29 | 8.92 | -11.35 | -748.96 | -13.91 |
EBT Excluding Unusual Items | 307.07 | 341.81 | 298.08 | 109.2 | -606.07 | 61.82 |
Impairment of Goodwill | - | - | -3.34 | - | - | - |
Gain (Loss) on Sale of Assets | 0.84 | 0.83 | 0.44 | 0.76 | 0.21 | 3.4 |
Asset Writedown | -7.64 | -0.76 | -1.4 | -0.05 | - | - |
Legal Settlements | -1.72 | -1.72 | -0.5 | -0.49 | -0.78 | -1.14 |
Other Unusual Items | 21.98 | 17.25 | 16.55 | 49.12 | 41.56 | 70.84 |
Pretax Income | 320.54 | 357.41 | 309.83 | 158.54 | -565.07 | 134.91 |
Income Tax Expense | 90.33 | 99.96 | 94.87 | 109.15 | 113.71 | 99.52 |
Earnings From Continuing Operations | 230.2 | 257.45 | 214.97 | 49.39 | -678.78 | 35.38 |
Minority Interest in Earnings | -69.17 | -74.4 | -87.97 | -44.5 | -10.45 | -16.65 |
Net Income | 161.04 | 183.06 | 126.99 | 4.89 | -689.23 | 18.73 |
Net Income to Common | 161.04 | 183.06 | 126.99 | 4.89 | -689.23 | 18.73 |
Net Income Growth | -3.18% | 44.15% | 2496.79% | - | - | -80.76% |
Shares Outstanding (Basic) | 1,710 | 1,711 | 1,716 | 1,630 | 1,715 | 1,702 |
Shares Outstanding (Diluted) | 1,710 | 1,711 | 1,716 | 1,630 | 1,715 | 1,702 |
Shares Change (YoY) | -0.92% | -0.31% | 5.27% | -4.92% | 0.70% | 4.96% |
EPS (Basic) | 0.09 | 0.11 | 0.07 | 0.00 | -0.40 | 0.01 |
EPS (Diluted) | 0.09 | 0.11 | 0.07 | 0.00 | -0.40 | 0.01 |
EPS Growth | -2.28% | 44.59% | 2366.67% | - | - | -81.67% |
Free Cash Flow | 627.68 | 634.53 | 445.35 | 401.23 | 454.81 | 502.75 |
Free Cash Flow Per Share | 0.37 | 0.37 | 0.26 | 0.25 | 0.27 | 0.29 |
Dividend Per Share | 0.035 | 0.035 | 0.030 | 0.010 | - | 0.060 |
Dividend Growth | 16.67% | 16.67% | 200.00% | - | - | 100.00% |
Gross Margin | 31.11% | 31.15% | 31.79% | 31.75% | 32.73% | 35.57% |
Operating Margin | 6.55% | 6.79% | 6.68% | 5.30% | 6.05% | 5.78% |
Profit Margin | 1.83% | 1.98% | 1.29% | 0.05% | -6.56% | 0.18% |
Free Cash Flow Margin | 7.12% | 6.87% | 4.51% | 3.96% | 4.33% | 4.84% |
EBITDA | 1,491 | 1,517 | 1,452 | 1,275 | 1,347 | 1,224 |
EBITDA Margin | 16.90% | 16.41% | 14.71% | 12.60% | 12.83% | 11.79% |
D&A For EBITDA | 913.47 | 889.37 | 792.99 | 739.01 | 712 | 624 |
EBIT | 577.45 | 627.16 | 658.87 | 536.44 | 634.8 | 600.11 |
EBIT Margin | 6.55% | 6.79% | 6.68% | 5.30% | 6.05% | 5.78% |
Effective Tax Rate | 28.18% | 27.97% | 30.62% | 68.85% | - | 73.77% |
Revenue as Reported | 8,821 | 9,242 | 9,870 | 10,120 | 10,500 | 10,385 |
Advertising Expenses | - | 109.62 | 119.86 | 133.01 | 127.89 | 185.19 |
Source: S&P Global Market Intelligence. Standard template. Financial Sources.